Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,622.40 106.13 0.73%
TOPIX 1,179.73 6.36 0.54%
HANG SENG 22,760.24 64.23 0.28%

Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement



 Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV
                   Assay as Potential Pap Smear Replacement

PR Newswire

SAN DIEGO, Calif., Nov. 27, 2012

SAN DIEGO, Calif., Nov. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:
 TROV) and the PIO XII Foundation, affiliated with Brazil's Barretos Cancer
Hospital, today announced that they entered into a research collaboration to
evaluate the performance of a urine-based molecular assay for detection of HPV
types associated with cervical lesions. The goal of the study is to determine
whether this assay can potentially replace Pap smears as the primary screen
for cervical cancer risk in Brazil's healthcare system. Barretos Cancer
Hospital, Brazil's preeminent center for oncology research and cancer
treatment, will conduct the study using Trovagene's proprietary, urine-based
method for determining the presence of high risk HPV types, allowing for
completely non-invasive HPV carrier screening.  

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

HPV infections are the leading cause of cervical cancer. In medically
underserved regions, traditional screening methods to detect elevated risk of
cervical cancer, such as a Pap smear, are not broadly available. In Brazil,
cervical cancer is the second most frequent tumor type in women and the
leading cause of cancer-related mortality in women 14 to 44 years of age.
Brazil has placed special emphasis on programs to improve HPV screening to
address this pressing healthcare need.

"We are excited to begin this important clinical trial using Trovagene's
proprietary urine-based HPV assay," says Adhemar Longatto Filho, M.Sc., Ph.D.,
PMIAC, from the Laboratory of Medical Investigation at the University of Sao
Paulo and principal investigator for the study at Barretos Cancer Hospital.
"This study can pave the way to make HPV screening broadly available to
medically underserved patients in our region. Our goal is to provide patients
with non-invasive testing options to determine their HPV risk factor and
significantly improve women's healthcare in Brazil."

"We are committed to work with Barretos Cancer Hospital to study the
performance of our proprietary HPV assay in Brazil. Improved logistics,
reduced costs and increased compliance can significantly increase HPV
screening rates and save lives," states Antonius Schuh, Ph.D., chief executive
officer of Trovagene. "This collaboration with Barretos is another important
step towards making Trovagene's non-invasive HPV carrier screen available in
key healthcare markets globally."

About PIO XII Foundation and Barretos Cancer Hospital.

PIO XII Foundation and Barretos Cancer Hospital – Barretos Cancer Hospital has
become the most important center of oncology research in Brazil. Barretos
Cancer Hospital provides patients with free treatments, including
chemotherapy, radiology, radiotherapy, surgeries, exams, and biopsies. Over
3,000 patients are treated daily, serving over 1,200 cities.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented
technology for the detection of transrenal DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that cross the
kidney barrier and can be detected in urine.  Trovagene is leveraging its
intellectual property in oncogene mutations via out-licensing and use of its
transrenal technologies to extend oncogene mutation detection using urine as a
sample.  As a non-invasive and abundant sample, urine may overcome many of the
cost and collection challenges associated with biopsy, as well as the volume
limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular
testing. It has U.S. and European patent applications and issued patents that
cover testing for HPV and other infectious diseases, cancer, transplantation,
prenatal and genetic testing. In addition, it owns worldwide rights to
nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia
(AML) and mutations in the SF3B1 gene, which have been shown to be associated
with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payer reimbursement; limited sales
and marketing efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement. 
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2011 and other periodic reports filed with the
Securities and Exchange Commission.

Contact
Trovagene, Inc.                            PIO XII Foundation – Barretos
                                           Cancer Hospital.
Michael Terry                              Adhemar Longatto Filho, M.Sc.,
                                           Ph.D., PMIAC
VP Corporate  Development                  Principal Investigator
+1 (858) 496-7641                          + 011 (5 5) 11 3061-7413.
mterry@trovagene.com                       longatto16@hotmail.com
www.trovagene.com                          www.hcancerbarretos.com.br

SOURCE Trovagene, Inc.

Website: http://www.trovagene.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement